Production (Stage)
NervGen Pharma Corp.
NGENF
$2.42
$0.19558.81%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.75M | -6.15M | -3.83M | -5.72M | -1.74M |
| Total Depreciation and Amortization | 9.70K | 11.30K | 10.70K | 11.00K | 28.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -376.30K | 2.99M | -34.50K | 2.35M | -827.00K |
| Change in Net Operating Assets | 247.70K | 531.00K | -363.00K | 303.70K | 129.70K |
| Cash from Operations | -2.87M | -2.61M | -4.22M | -3.06M | -2.41M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 17.60K | 18.00K | 18.50K | 6.10K | -- |
| Cash from Investing | 17.60K | 18.00K | 18.50K | 6.10K | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -25.20K | -25.20K | -25.20K | -25.20K | -25.20K |
| Issuance of Common Stock | 1.76M | 335.20K | 295.00K | 164.00K | 23.63M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -460.20K | 0.00 | 0.00 | -27.40K | -1.60M |
| Cash from Financing | 888.00K | 221.50K | 197.80K | 81.30K | 16.32M |
| Foreign Exchange rate Adjustments | 15.90K | -297.30K | -68.60K | 231.70K | -83.30K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.95M | -2.67M | -4.07M | -2.74M | 13.83M |